Impact of medicaid prior authorization on angiotensin-receptor blockers: Can policy promote rational prescribing?

Health Affairs

Volumn 26, Issue 3, 2007, Pages 800-807

  Fischer, Michael A ^a   Choudhry, Niteesh K ^a   Winkelmayer, Wolfgang C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT;

ARTICLE; CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG USE; ECONOMICS; HUMAN; HYPERTENSION; MEDICAID; REIMBURSEMENT; STATISTICS; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; DRUG UTILIZATION REVIEW; HUMANS; HYPERTENSION; MEDICAID; PHYSICIAN'S PRACTICE PATTERNS; RECEPTORS, ANGIOTENSIN; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 34248546143     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.3.800     Document Type: Article

References (28)

1. See, for example, J. Tilly and L. Elam, "Prior Authorization for Medicaid Prescription Drugs in Five States: Lessons for Policy Makers" (Washington: Henry J. Kaiser Family Foundation, 2003);
2. W.E. Smalley et al., "Effect of a Prior-Authorization Requirement on the Use of Nonsteroidal Antiinflammatory Drugs by Medicaid Patients," New England Journal of Medicine 332, no. 24 (1995): 1612-1617;
3. and E.E. Roughead et al., "Differential Effect of Early or Late Implementation of Prior Authorization Policies on the Use of Cox II Inhibitors," Medical Care 44, no. 4 (2006): 378-382.
4. B. Bruen and A. Ghosh, "Medicaid Prescription Drug Spending and Use" (Washington: Kaiser Commission on Medicaid and the Uninsured, 2004).
5. M.A. Fischer et al., "Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors," New England Journal of Medicine 351, no. 21 (2004): 2187-2194;
6. and M.M. Mello, D.M. Studdert, and T.A. Brennan, "The Pharmaceutical Industry versus Medicaid - Limits of State Initiatives to Control Prescription-Drug Costs," New England Journal of Medicine 350, no. 6 (2004): 608-613.
7. A.V. Chobanian et al., "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report," Journal of the American Medical Association 289, no. 19 (2003): 2560-2572.
8. T. Thom et al., "Heart Disease and Stroke Statistics - 2006 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee," Circulation 113, no. 6 (2006): e85-e151.
9. "Effects of Enalapril on Mortality in Severe Congestive Heart Failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)," New England Journal of Medicine 316, no. 23 (1987): 1429-1435;
10. "Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure," New England Journal of Medicine 325, no. 5 (1991): 293-302;
11. M. Marre et al., "Prevention of Diabetic Neuropathy with Enalapril in Normotensive Diabetics with Microalbuminuria," British Medical Journal 297, no. 6656 (1988): 1092-1095;
12. and E.J. Lewis et al., "The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy," New England Journal of Medicine 329, no. 20 (1993): 1456-1462.
13. E.J. Lewis et al., "Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes," New England Journal of Medicine 345, no. 12 (2001): 851-860;
14. and B.M. Brenner et al., "Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy," New England Journal of Medicine 345, no. 12 (2001): 861-869.
15. K. Dickstein et al., "Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients after Acute Myocardial Infarction: The OPTIMAAL Randomised Trial," Lancet 360, no. 9335 (2002): 752-760;
16. and M.A. Pfeffer et al., "Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both," New England Journal of Medicine 349, no. 20 (2003): 1893-1906.
17. Red Book (Montvale, N.J.: Thomson PDR, 2005).
18. IMS Health, "Leading Ten Therapeutic Classes by U.S. Sales, 2005," 2006, http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6599_73915261_77140565,00.html (accessed 6 April 2006).
19. Centers for Medicare and Medicaid Services, "State Drug Utilization Data," 2005, http://www.cms.hhs.gov/MedicaidDrugRebateProgram/SDUD/list. asp#TopOfPage (accessed 11 October 2005).
20. World Health Organization, Collaborating Centre for Drug Statistics Methodology, "New ATC/DDD Index," January 2007, http://www.whocc.no/ atcddd (accessed 23 February 2007).
21. CMS, "Data Compendium, 2006 Edition," February 2007, http://www.cms.hhs.gov/DataCompendium/18_2006_Data_Compendium.asp#TopOfPage (accessed 14 March 2007).
22. Smalley et al., "Effect of a Prior-Authorization Requirement";
23. and D.M. Hartung et al., "Effects of a Prior-Authorization Policy for Celecoxib on Medical Service and Prescription Drug Use in a Managed Care Medicaid Population," Clinical Therapeutics 26, no. 9 (2004): 1518-1532.
24. Roughead et al., "Differential Effect"; and Fischer et al., "Effect of Medicaid Prior-Authorization Programs."
25. Red Book.
26. National Pharmaceutical Council, "Pharmaceutical Benefits under State Medical Assistance Programs" (Reston, Va.: NPC, 2004).
27. Dickstein et al., "Effects of Losartan and Captopril" and Pfeffer et al., "Valsartan, Captopril, or Both."
28. W.H. Shrank et al., "The Implications of Choice: Prescribing Generic or Preferred Pharmaceuticals Improves Medication Adherence for Chronic Conditions," Archives of Internal Medicine 166, no. 3 (2006): 332-337.